Illinois Municipal Retirement Fund lessened its stake in Elevance Health, Inc. (NYSE:ELV – Free Report) by 2.8% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 62,010 shares of the company’s stock after selling 1,810 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Elevance Health were worth $18,153,000 as of its most recent SEC filing.
A number of other hedge funds have also recently modified their holdings of ELV. Kemnay Advisory Services Inc. acquired a new stake in Elevance Health during the fourth quarter worth about $31,000. J.Safra Asset Management Corp acquired a new position in Elevance Health in the fourth quarter valued at approximately $32,000. ORG Partners LLC lifted its holdings in Elevance Health by 120.4% in the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after acquiring an additional 59 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in Elevance Health in the 4th quarter worth approximately $38,000. Finally, Dorato Capital Management purchased a new stake in Elevance Health in the 4th quarter worth approximately $41,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.
Analysts Set New Price Targets
Several research firms have recently weighed in on ELV. Evercore reaffirmed a “hold” rating on shares of Elevance Health in a report on Tuesday, May 19th. Truist Financial increased their price target on shares of Elevance Health from $450.00 to $475.00 and gave the stock a “buy” rating in a report on Tuesday. Deutsche Bank Aktiengesellschaft upgraded shares of Elevance Health from a “hold” rating to a “buy” rating and raised their price target for the company from $363.00 to $498.00 in a research report on Wednesday, May 20th. Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday. Finally, Weiss Ratings upgraded shares of Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, May 18th. Fifteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, Elevance Health currently has an average rating of “Moderate Buy” and a consensus price target of $435.05.
Insider Transactions at Elevance Health
In other news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the sale, the director owned 10,734 shares in the company, valued at $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.34% of the stock is currently owned by insiders.
More Elevance Health News
Here are the key news stories impacting Elevance Health this week:
- Positive Sentiment: Elevance Health beat Q2 estimates, reporting EPS of $7.45 versus $6.18 expected and revenue of $49.83 billion versus $48.84 billion projected. Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
- Positive Sentiment: The company raised its 2026 adjusted EPS guidance to at least $27.00, suggesting management expects improved operating performance and better medical cost control ahead. Elevance raises annual profit forecast on better medical cost management
- Positive Sentiment: Management said results were supported by disciplined execution, improved operating performance, and lower medical costs in some plans, which could help margins recover. Elevance Health Profits Eclipse $1.4 Billion As Costs Ease Somewhat
- Neutral Sentiment: Elevance also announced a quarterly dividend of $1.72 per share, reinforcing its shareholder-return profile. MarketBeat dividend notice
- Negative Sentiment: Despite the beat, the stock is being pressured by margin concerns, including a higher benefit-expense ratio and ongoing cost pressure in parts of the business. Elevance Health Raises Earnings Outlook on Higher Sales
- Negative Sentiment: Year-over-year EPS fell from $8.84, and softer membership plus higher expenses suggest earnings momentum is not yet fully stable. ELV Beats Q2 Earnings Estimates on Higher CarelonRx Product Revenues
Elevance Health Stock Down 8.7%
Elevance Health stock opened at $389.85 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The stock has a market capitalization of $84.66 billion, a PE ratio of 16.58, a price-to-earnings-growth ratio of 2.42 and a beta of 0.67. The business has a 50 day simple moving average of $399.67 and a 200-day simple moving average of $355.07. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $436.24.
Elevance Health (NYSE:ELV – Get Free Report) last announced its earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.21 by $1.24. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm had revenue of $49.83 billion for the quarter, compared to analyst estimates of $48.88 billion. During the same quarter last year, the firm posted $8.84 EPS. The business’s revenue was up .8% on a year-over-year basis. On average, analysts anticipate that Elevance Health, Inc. will post 26.86 EPS for the current fiscal year.
Elevance Health Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be given a dividend of $1.72 per share. The ex-dividend date is Thursday, September 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. Elevance Health’s dividend payout ratio is currently 29.26%.
Elevance Health Profile
Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.
Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.
Read More
- Five stocks we like better than Elevance Health
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
